Accordingly, we propose that upregulation of tumor-suppressive KRT7-AS in cancer cells is a sensible strategy for developing novel therapeutics against lung and breast cancers, and other KRT7-AS deficient malignant tumors as well. Here, KRT7 is linked to breast cancer.